<DOC>
	<DOCNO>NCT02203864</DOCNO>
	<brief_summary>Evaluation safety tolerability four intradermal injection give two week interval . In addition efficacy transferrinfection determine quantify Interleukin 2 ( IL-2 ) , locally produce implant , transfected allogenic melanoma cell injection site . Further determination tumor specific clinical host response induce augmented treatment determine .</brief_summary>
	<brief_title>Dose Escalation Study Evaluate Safety Tolerability Allogeneic Tumor Vaccine BIWB 2 Patients With Advanced Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Patients fail respond conventional therapy conventional therapy available Metastatic melanoma ( stage IV AJCC ) surgically medically incurable distant metastatic disease ( i.e. , metastasis lymph node drain area primary malignant melanoma ) . Histologic confirmation stage IV require . Measurable disease routinely assess physical examination and/or noninvasive radiological procedure Karnofsky performance status least 60 % life expectancy great 4 month Male female , minimum age 18 year Written inform consent patient accordance good clinical practice local legislation Availability material autologous Delayed Type Hypersensitivity ( DTH ) test ( material derive autologous melanoma metastasis inhouse preparation successful ) requisite enter study Patients undergo biopsy least one metastasis first last vaccination Patient receive chemotherapy , corticosteroid , radiotherapy ( stereotactic irradiation permit ) , immunotherapy ( e.g . Granulocyte Macrophage Colony Stimulating Factor , Granulocyte Colony Stimulating Factor ) investigational drug 4 week prior first vaccination prior surgical removal tumor specimens DTH material preparation ( patient permit receive therapy 4 week prior first cell inoculation except tumor reductive surgery medically indicate ) Patients active intracranial metastasis ( CT/MRI ) choroidal melanoma Patients active autoimmune disease Patients organ allografts Patients evidence one follow infection : HIV1 , HIV2 , Hepatitis B Virus , Hepatitis C Virus , Human T lymphotropic Virus1 Patients active systemic infection major medical illness cardiovascular organ system [ e.g . coronary heart disease ( New York Heart Association class III IV ) , history clinically significant ventricular arrhythmia angina ] , coagulation disorder , respiratory nervous system disorder severe endocrinological disease Women childbearing potential positive pregnancy test without appropriate contraception ( e.g . IUD [ IntraUterine Device ] , oral contraceptive ) least 28 day last vaccination Lactating woman Impaired renal hepatic function ( serum creatinine &gt; 1.5 mg/dl creatinine clearance &lt; 75 ml/min ) . In amendment 1 3 serum creatinine level change 2.5 mg/dl creatinine clearance reduce 30 ml/min Impaired hematologic function : White Blood Count ( WBC ) &lt; 2500/mm**3 absolute lymphocyte count &lt; 1500/mm**3 hemoglobin &lt; 8 g/dl platelet &lt; 100,000/mm**3 Evidence existence history malignant neoplasm ( except adequately treat basal cell carcinoma carcinoma situ cervix )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>